Cargando…

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

Dabrafenib is an oral BRAF kinase inhibitor approved for the treatment of various BRAF V600 mutation–positive solid tumors. In vitro observations suggesting cytochrome P450 (CYP) 3A induction and organic anion transporting polypeptide (OATP) inhibition prompted us to evaluate the effect of dabrafeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nebot, Noelia, Won, Christina S., Moreno, Victor, Muñoz‐Couselo, Eva, Lee, Dung‐Yang, Gasal, Eduard, Bouillaud, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453865/ https://www.ncbi.nlm.nih.gov/pubmed/33932130 http://dx.doi.org/10.1002/cpdd.937

Ejemplares similares

Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
por: Suga, Takahiro, et al.
Publicado: (2017)

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
por: Schnegelberger, Regina D., et al.
Publicado: (2022)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5
por: Hua, Wen Jin, et al.
Publicado: (2014)

Selectivity and Potency of Microcystin Congeners against OATP1B1 and OATP1B3 Expressing Cancer Cells
por: Niedermeyer, Timo H. J., et al.
Publicado: (2014)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
por: Elsby, Robert, et al.
Publicado: (2023)

Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
por: Windt, Tímea, et al.
Publicado: (2019)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRα
por: Liu, Mingyi, et al.
Publicado: (2020)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1
por: Patik, Izabel, et al.
Publicado: (2018)

Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions
por: Alam, Khondoker, et al.
Publicado: (2018)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
por: Trdan Lušin, Tina, et al.
Publicado: (2012)

Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro
por: Ishikawa, Rika, et al.
Publicado: (2023)

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates
por: Haberer, Lynda J., et al.
Publicado: (2013)

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
por: Yoshikado, Takashi, et al.
Publicado: (2018)

Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models
por: Kotsampasakou, Eleni, et al.
Publicado: (2015)

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner
por: Alam, Khondoker, et al.
Publicado: (2017)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Curated human hyperbilirubinemia data and the respective OATP1B1 and 1B3 inhibition predictions
por: Kotsampasakou, Eleni, et al.
Publicado: (2017)

Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance
por: Hovd, Markus, et al.
Publicado: (2023)

Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates
por: Medwid, Samantha, et al.
Publicado: (2021)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells
por: Brännström, Marie, et al.
Publicado: (2015)

Influence of OATP1B1 and OATP1B3 mutations and glomerular filtration rate on trough serum digoxin concentration in the Chinese population: A prospective cohort study
por: Chen, Shu-qing, et al.
Publicado: (2019)

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
por: Heinig, Roland, et al.
Publicado: (2022)

Inhibitory Effects of Green Tea and (–)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein
por: Knop, Jana, et al.
Publicado: (2015)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates–Fexofenadine in Taiwanese?
por: Chen, Y. A., et al.
Publicado: (2015)

Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis
por: Li, Rui, et al.
Publicado: (2017)

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances
por: Emami Riedmaier, Ariane, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fic0hpf39ees0780s8eq04cp0g